"I take the fight against cancer personally. I lost my father to esophageal cancer. I understand the disruption cancer causes in a family. Attempting to understand the disease, treatment options, and make life changing decisions can seem overwhelming.
I strive to help each patient and family gain knowledge of their disease and treatment options so they are well prepared to make the best decisions possible. I have focused my time and efforts to develop an expertise in Urological Cancers.
I remain active in patient care, research, and national committees for these tumors to ensure that I provide superior patient advice."
Urological Cancers (Prostate, Kidney, Bladder Cancer and Testicular Cancers)
World-class prostate cancer background from Memorial Sloan Kettering Cancer Center
Expert panel member for the development of National Prostate Cancer Treatment Guidelines
A selected CALGB member designing new research studies for Prostate & Urologic Cancers across the nation
Click here to watch Dr Nordquist and Mike Simmonds discuss the critical importance of second opinions.
Get A Second Opinion
Click here to request a second opinion.
This Sunday on Cancer Opinions with Dr. Luke, we will be speaking with Dr David Hung, the CEO of Medivation. It is a biotech company that just recently released a major prostate cancer drug called Xtandi.
David Hung, M.D.
President and Chief Executive Officer, Director
Dr. Hung served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004.
From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. ProDuct Health, Inc was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs.
From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects.
Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.
Please click here to listen to a previous interview with Dr. Hung.
Click here for more information
Great advances allowing for new treatment options for Urologic Cancers are being studied at selected centers across the United States.
Dr. Nordquist's team actively pursues and participates in the most advanced treatments available through a national network of research partners including major cancer centers, universities and pharmaceutical companies.
On Sunday, October 7 show, we will discuss the challenges cancer patients face after winning their battle with cancer.
Additional resource information
Free, professional support for anyone affected by cancer
Oncology social workers help you cope with the emotional and practical challenges of cancer. Contact us at 800-813-HOPE (4673)